Childhood Hodgkin Lymphoma Treatment (PDQ®)—Health Professional Version - National Cancer Institute

Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (12/13/2018)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

This summary was reformatted.

Treatment of Newly Diagnosed Children and Adolescents with Hodgkin Lymphoma

Revised Table 8 to include the results of a Children's Oncology Group study that treated patients with low-risk nodular lymphocyte-predominant Hodgkin lymphoma with surgery only.

Treatment of Primary Refractory or Recurrent Hodgkin Lymphoma in Children and Adolescents

Added Checkpoint inhibitor therapy as a new subsection.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Late Effects From Childhood/Adolescent Hodgkin Lymphoma Therapy

Next section >
About This PDQ Summary